Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS

Glut1 Deficiency Syndrome Clinical Trial

— GLUT-HEP  

Official title:

Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02014883
• Other study ID #: C13-37
• Secondary ID: 2013-A01300-45
• Status: Completed
• Phase: Phase 2
• Start date: December 4, 2013
• Est. completion date: July 4, 2019

Study information

• Verified date: August 2021
• Source: Institut National de la Santé Et de la Recherche Médicale, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this project is to study the efficacy of triheptanoin oil in patients with GLUT1 deficiency syndrome.

Description:

The primary objective of the study is: - to evaluate the capacity of triheptanoïn to improve the condition of patients with GLUT1-DS The secondary objectives of the study are: - to confirm the short-term safety of triheptanoïn therapy in patients with GLUT1-DS - to evaluate the short-term effects of triheptanoïn treatment on motor function, autonomy, quality of life and clinical signs of patients with GLUT1-DS - to evaluate the effect of triheptanoïn on brain energy metabolism using non-invasive 31P-MRS spectroscopy after activation of the occipital cortex in order to measure the levels of high-energy phosphates (such as ATP and phosphocreatine)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: July 4, 2019
• Est. primary completion date: July 4, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years and older

Eligibility

Inclusion Criteria:

• Mutation in SLC2A1 gene
• Age > 3 years
• Patient with history/frequency of seizures or movement disorders documented at least 3 months prior to the beginning of the study
• Covered by french social security
• Patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent. (In addition to the requirement for the consent of parents or the legal representative, adolescents can provide additional informed consent to participate in clinical trials)

Exclusion Criteria:

• Evidence of psychiatric disorder
• Attendant neurological disorder
• Comorbid medical condition that would render them unsuitable for the study, e.g. HIV, diabetes
• Pregnant or parturient or lactating women
• Unwillingness to be informed in case of abnormal MRI
• Failure to give written informed consent
• Unable to understand the protocol
• Unable to participate to the whole study
• Absence of signed informed consent
• Persons deprived of their liberty by judicial or administrative decision
• Person subject to an exclusion period for another research
• Subjects with exclusion criteria required by french law

Related Conditions & MeSH terms

• Glut1 Deficiency Syndrome

Intervention

Drug:
• GLUT1 DS

Locations

Country	Name	City	State
France	Brain and Spine Institute	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Institut National de la Santé Et de la Recherche Médicale, France	Ultragenyx Pharmaceutical Inc

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of paroxystic events	The number of paroxystic events, in particular abnormal movements, will be collected during trihepatnoin treatment.	6 months
Secondary	Safety	Should the whole blood levels of propionylcarnitine increase above 8 µmol/l, the dose of triheptanoin will be reduced until the decrease of whole blood propionylcarnitine is below 8 µmol/l. Should an organic acid abnormality such as an excessive urinary excretion of propionate metabolites such as 3-hydroxypropionic, 2-methylcitric, propionylglycine, tiglylglycine and/or methylmalonic acid occur, the dose of triheptanoin will be reduced until normalization of the organic acid and acylcarnitine profile. If still abnormal, patient will be excluded from the study. For GI distress, the research dietitian will instruct the patient regarding taking the dose over a longer period of time (30 minutes). If GI distress persists, triheptanoin dose will be reduced by 50% and re-increased progressively as the problems resolve with the patients working closely with research dietitian until tolerance of the full dose is achieved.	6 months
Secondary	6 minutes walk test		6 months
Secondary	9 hole Peg board		6 months
Secondary	Clinical Global Impression Scales		6 months
Secondary	Schwab-England scale		6 months
Secondary	Vineland Scale		6 months
Secondary	Fatigue Severity Scale		6 months
Secondary	Fatigue Visual Scale		6 months
Secondary	Brain 31phosphorus magnetic resonance spectroscopy	Ratio of Inorganic Phosphate (Pi) over Phosphocreatine during visual stimulation	6 months